Sdi Share Discussion Threads

[rivaldo] 15/11/2017 23:10

A late tick up.....with 200,000 shares reported bought after the close tonight at 24.4p.

[rivaldo] 02/11/2017 23:26

Agreed AISHAH. I think your buying will be well rewarded.

Nice £10,000 buy at 22.99p just before the close.

[aishah] 02/11/2017 09:51

I've been adding below 22p whilst seller persists. Looks cheap on forecasts imo.

[rivaldo] 30/10/2017 13:38

News:



"Thursday 26th October 2017

G:BOX Chemi XRQ used at top biochemistry school

Cambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, today announced its G:BOX Chemi XRQ multi-application imager is being used in the School of Biochemistry at the University of Bristol, one of UK’s best biochemistry departments, in the laboratory of Prof. Jo Adams, to rapidly generate more accurate images of extracellular matrix (ECM) proteins associated with fibrosis, angiogenesis and wound healing.

Researchers in the School of Biochemistry are using a G:BOX Chemi XRQ multi-application system for imaging ECL-based chemiluminescent Western blots to accurately detect changes in thrombospondins, secreted glycoproteins of the extracellular matrix. The data produced are providing information which the scientists at the University of Bristol are using to understand how these proteins regulate the interaction between cells and the ECM.

etc"

[buywell3] 26/10/2017 19:30

I think a takeover offer is coming

My call at this share price is 30p a share

[rivaldo] 26/10/2017 13:46

Looks like a forced seller out there. I've just topped up with a few more.

Forecasts are 1.9p EPS this year rising to 2.2p EPS next year - SDI are now on a single-figure forward P/E.

[rivaldo] 10/10/2017 23:13

Another large buy reported at the close, this time a £61,000 buy of 250k shares at 24.5p.

[nedelcu77] 09/10/2017 18:40

1.25% of sdi traded, 276k worth.maybe last of oryx stock

[rivaldo] 09/10/2017 14:40

...make that almost £100,000 of buys at 24.5p today following a 150,000 buy.

[rivaldo] 09/10/2017 13:26

Good to see £61,000 of buys at 24.5p this morning in two chunks.

[garbetklb] 05/10/2017 11:04

I was the other shareholder present. Thanks Hastings for an excellent summary - I've v little to add.

Re dividend - my take was that there wasn't much point in a nominal dividend as people would immediately focus on how small it was. Prefer money to be ploughed back into the business in the immediate future. when a dividend comes, it should be meaningful.

I think the position re ProReveal is pretty scandalous - the machines cost significantly less than I thought and in view of the potential latent problems building up, this should be a NHS priority. KF/MC think the Dept Health may find the small amount needed to get cleaning centres equipped - about 250 centres needing 1-2 machines each at around £10k per machine. So something of the order of £5m to fully equip the NHS which is pretty trivial in the context of health spending.

I share Hastings' view of the company - a reasonably safe steady growth company.

We hold in reasonable size.

[cockerhoop] 02/10/2017 16:48

Thanks for the summary hastings

The obvious difference between SDI and JDG is the former has almost quadrupled the shares in issue since 2012 to double turnover whilst the latter has more than doubled turnover and whilst issuing only 33% more shares in the same period.

[pj 1] 02/10/2017 16:47

Yes many thanks Hastings.

[rhomboid] 02/10/2017 16:28

Thanks Hastings, nice summary, this is a great GARP holding from these levels, albeit I'd rather hoped the ProReveal obvious advantages would have been dramatic & critical enough to overcome the sloth like NHS procurement process. I'm hoping that it doesn't become a scandal of the type which is still unwinding with infected blood being transfused long after the dangers & precautions were abundantly clear to those in charge.

The snippet re Judges was fascinating,their progress has been spectacular over the years I've watched it as a non shareholder 🙄

[hastings] 02/10/2017 15:38

Hi rivaldo
thanks for popping that up, further underlines the commitment to bring new or upgraded products to market.

As for the AGM, not that much to report other than what is below.


There was only one other private shareholder present and he had travelled considerably further than me, coming all the way down from Scotland.

As far as the board went, all Directors were present with the addition of representatives from each division of the group, so it was nice to be able to ask a few questions to new faces.

Although the meeting was reasonably short Ken Ford (Chairman) reiterated the message as in the release that morning regarding trading being in line with expectations and that they view the current financial year very positively.

Some points of interest, the other shareholder present asked as to how they identify the acquisition targets.

Ford introduced us to a seemingly very knowledgeable chap (name escapes me) who for a number of years was employed by Judges Scientific but who has more recently been assisting SDI in this field.
The man in question pointed out that there are numerous company's out there for SDI to acquire as the space is very fragmented. However, it takes time and a lot of groundwork to secure the right fit.
Ford and Creedon are of course deeply involved in the process and work with him in this area.
It was also added, that when you have made a few of these buys, subjects begin to seek you out as opposed to the other way round, which can make the process somewhat easier.

Suffice to say though that they are not at present ready for another buy, but continue to look pointing out it is very much key to their progression.
My conclusion is that I think we can assume that there will be another one in the not so distant future.

All current arms are profitable and going well, even the Synoptics business, which although enjoying a chunk of sizeable revenue has struggled over the years.

Creedon said cost savings, reorganisation and new products have turned this around.

Pro-Reveal continues to make progress albeit slowly and they are currently (still) waiting to hear back on the potential for a procurement programme from the DOH/NHS.

That would be very welcome and provide for a really good boost.

They aren't however surprised by the timing or for that matter seemingly concerned, as they view the product as a potentially nice edition to the rest and it is certainly in the right place given the guidance etc, so it remains a case of waiting and watching with that.

In terms of a future placing (not on the cards at present) they are aware of retail investor interest and would now certainly consider making some kind of provision alongside an institutional placing, the latter of which they say would see plenty of support.

I asked the question if Brexit presented any worries for any arms of the business, but each head said that was not of concern to them and they couldn't envisage any problems.

Ford also asked the two of us present our views on commencing dividend payments, which he said when/if implemented would be very well covered.

For my part, I said that I would rather see the money ploughed back into the business until a scaling up had been reached that would ensure a sustainable progressive dividend for the medium to long term as opposed to a sort of token dividend that some companies often opt for.

All in all, there seems to be a really positive mood prevailing, although they clearly do not want to overplay anything and Creedon just tells it as it is.

That said I can envisage at some point an upgrade coming through as they certainly have some decent businesses going well with prospects for organic growth that can be enhanced by further bolt-on buys.

For now at the current price of 23.5p the shares do not look expensive to me trading on a PER of 11 falling to 10 (sector average is 19) with a PEG of 0.7 which looks well worth holding on to in the near term, with scope for further upside in the future.

As I say not much to report but gives a flavour for those not present.

[rivaldo] 02/10/2017 14:45

Looking forward to the presentation in London, which should bring in some more interest.

Hastings, looking forward to your AGM observations.

Meanwhile, news of another product launch:



"Wednesday 27th September 2017

Launch of NEW Chromogenic ID Media Software Module for ISO® 9308-1 Compliant Plates

Cambridge, UK: Synbiosis, a long-established, expert manufacturer of automated microbiological systems, today announced its Chromogenic ID software for use with Synbiosis colony counters has a new validated module for automatic identification of bacteria cultured on Liofilchem and Merck ISO 9308-1 compliant chromogenic media. Using this upgraded software allows microbiologists to precisely identify a range of coliforms in drinking water and disinfected pool water.

The new Chromogenic ID software module for use with Synbiosis ChromoZona, ProtoCOL 3, and Protos 3 automated colony identification systems, guarantees that using these systems’ patent digital colour imaging technology microbiologists can generate true to life colour plate images of E.coli and coliforms cultured on Liofilchem Chromatic™ Coliform Agar ISO and Merck’s Chromocult® Coliform Agar.

By analysing the plate images, the Chromogenic ID software can easily distinguish between purple/violet and salmon pink/red colonies, providing quick identification of E. coli, Klebsiella spp., Enterobacter spp. and Citrobacter spp.on these ISO® 9308-1 compliant chromogenic plates. This reduces misidentification, providing consistent data no matter when or which microbiologist is reading the plate. The plate images can then be stored in a secure SQL database for cross checking if necessary, and means the software is ideally suited for use in quality accredited testing laboratories.

To find out more about this exciting new Chromogenic ID Media Software Module scientists can click the link: hxxp://www.synbiosis.com/chromogenic-id/

“Eye identification of bacteria using chromogenic media depends on the lighting above and below the plate, as well as the colour vision and experience of the microbiologist” comments Kate George, Sales & Technical Director at Synbiosis. “Our new software module for Liofilchem and Merck’s ISO 9308-1 compliant plates is a great solution to the problems associated with this error prone manual method creating a standardised, consistent and objective test. This means scientists using ChromoZona, ProtoCOL 3 and Protos 3 systems can be confident of correctly identifying water borne pathogens every time.”

[pyemckay] 28/9/2017 09:30

that would be great hastings , look forward to your thoughts if you have time

[cockerhoop] 28/9/2017 09:02

Cheers hastings,

Was hoping to see them present in October at the Manchester Sharesoc event but they've withdrawn which is disappointing.

[hastings] 28/9/2017 07:01

I went along to the AGM on Tuesday being one of only two retail investors.Came away very happy with my investment and the companies prospects.I'll try and add a few words/observations this evening.

[rivaldo] 26/9/2017 09:48

SDI have today confirmed they're on track for at least 1.94p EPS this year, rising to 2.22p EPS next year.

That's a P/E of 11.8 falling to 10.4.

And a PEG of just 0.72, which also flags terrific value.

And yet the only trade so far today is a 5k buy.

The market will wake up to this at some point and re-rate the company a quick 30%-40% to 30p-32p imo. With more upside potential on another acquisition.

[hastings] 26/9/2017 07:37

Lol. Actually, you aren't far off the mark with that!

[pugugly] 26/9/2017 07:25

hastings - Take care and remember to wear helmet and body cam to protected yourself and record any rogue motorists and lorries !!

[hastings] 26/9/2017 07:18

Yes, also sounds pretty positive to me.I have got the bike all ready to peddle down to the AGM and will probably pen something later.